Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 2Plasma cell 1

Conditions

Multiple Myeloma 31Recurrence 5Waldenstrom Macroglobulinemia 1Neoplasm, Residual 1Leukemia, Plasma Cell 1Infections 1Immunoglobulin Light-chain Amyloidosis 1Hematologic Neoplasms 1Cytokine Release Syndrome 1

Interventions

fludarabine phosphate 19fludarabine 18Cyclophosphamide 16Tacrolimus 12Whole-Body Irradiation 11Melphalan 11Mycophenolic Acid 10Bortezomib 9Busulfan 8trametinib 7Dexamethasone 7thymoglobulin 6Stem Cell Transplantation 6Lenalidomide 6Cyclosporine 6Sirolimus 5Nivolumab 5Methotrexate 5dabrafenib 4Rituximab 4Peripheral Blood Stem Cell Transplantation 4Granulocyte Colony-Stimulating Factor 4Antilymphocyte Serum 4Alemtuzumab 4daratumumab 3aldesleukin 3Thiotepa 3Specimen Handling 3Ipilimumab 3Interleukin-2 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Hematologic Neoplasms × talquetamab × Plasma cell × Clear all
NCT04634552 2026-06-05

MonumenTAL-1

Janssen Research & Development, LLC

Phase 2 Recruiting
510 enrolled 1 FDA
Other hematologic neoplasmPlasma cell

Multiple Myeloma, Hematologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡